Longeveron (LGVN) Receivables - Net (2020 - 2026)
Longeveron's (LGVN) quarterly Receivables - Net came in at $68000.0 in Q1 2026, up 134.48% year-on-year from $29000.0 in Q1 2025, and down 34.62% quarter-over-quarter from $104000.0 in Q4 2025.
Longeveron (LGVN) Receivables - Net (2020 - 2026) Analysis & Trends
Longeveron's Receivables - Net history runs 7 years deep, the most recent figure standing at $68000.0 for Q1 2026.
- On a quarterly basis, Receivables - Net rose 134.48% year-over-year to $68000.0 in Q1 2026; TTM through Mar 2026 was $68000.0, a 134.48% increase from a year earlier, with the FY2025 full-year figure at $104000.0, up 23.81% from the prior year.
- Receivables - Net declined to $68000.0 in Q1 2026 per LGVN's latest filing, from $104000.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $380000.0 in Q3 2024 and bottomed at $29000.0 in Q1 2025.
- The 5-year median for Receivables - Net is $96000.0 (2022), against an average of $127647.1.
- Across the five-year window, Receivables - Net surged 296.36% in 2022 and plunged 86.32% in 2025, its largest moves.
- Year by year, Receivables - Net stood at $218000.0 in 2022, then sank by 49.08% to $111000.0 in 2023, then declined by 24.32% to $84000.0 in 2024, then advanced by 23.81% to $104000.0 in 2025, then slumped by 34.62% to $68000.0 in 2026.
- Per Business Quant, the three latest LGVN Receivables - Net figures stand at $68000.0 (Q1 2026), $104000.0 (Q4 2025), and $52000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68,000.00 |
| Mar 31, 2026 | 68,000.00 |
| Dec 31, 2025 | 104,000.00 |
| Dec 31, 2025 | 104,000.00 |
| Sep 30, 2025 | 52,000.00 |
| Sep 30, 2025 | 52,000.00 |
| Jun 30, 2025 | 31,000.00 |
| Jun 30, 2025 | 31,000.00 |
| Mar 31, 2025 | 29,000.00 |
| Mar 31, 2025 | 29,000.00 |
| Dec 31, 2024 | 84,000.00 |
| Dec 31, 2024 | 84,000.00 |
| Sep 30, 2024 | 380,000.00 |
| Sep 30, 2024 | 380,000.00 |
| Jun 30, 2024 | 218,000.00 |
| Jun 30, 2024 | 218,000.00 |
| Mar 31, 2024 | 178,000.00 |
| Mar 31, 2024 | 178,000.00 |
| Dec 31, 2023 | 111,000.00 |
| Dec 31, 2023 | 111,000.00 |